{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-092644","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2024-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.211882+00:00","generated_at":"2026-05-31T07:46:28.634079+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Theriva Biologics effects 1-for-25 reverse stock split to meet NYSE American price rules","bullets":["Reverse split ratio of 1-for-25; shares reduced from 25,131,230 to approximately 1,005,249.","Effective 12:01 a.m. ET on August 26, 2024; trading began on post-split basis same day.","No fractional shares issued; holders otherwise entitled to fractional shares receive rounding up to next whole share.","Exercise price and share count under options, warrants, and equity plans adjusted proportionately.","Trading symbol unchanged ('TOVX'); new CUSIP number is 87164U508."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-092644","json":"https://secwatch.observer/filing/0001104659-24-092644.json","markdown":"https://secwatch.observer/filing/0001104659-24-092644.md","text":"https://secwatch.observer/filing/0001104659-24-092644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465924092644/0001104659-24-092644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465924092644/tm2422579d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:46:28.634079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}